Inovio Pharmaceuticals, Inc. Announces Management Appointments
May 24, 2018 at 08:00 am EDT
Share
Inovio Pharmaceuticals, Inc. announced that Mr. Shawn D. Bridy joins the company as Vice President of Business Development reporting to Dr. J. Joseph Kim, President & CEO. Mr. Bridy has more than 20 years of business development & licensing, commercial strategy, and transaction experience in the life sciences industry. He previously held strategic business development roles at large pharma companies and smaller biotechs including GSK, Elan, BTG plc and Immunome. Most recently he was Managing Director of Bridy Advisors. Inovio has also promoted Dr. Kate E. Broderick, Ph.D., to Vice President, Preclinical Research & Development reporting to Dr. Laurent Humeau, Senior Vice President, R&D. In her new position, Dr. Broderick will continue to spearhead Inovio's efforts to secure non-dilutive strategic R&D funding opportunities to support the research and clinical testing of Inovio's candidate vaccines. Dr. Broderick has previously led Inovio's efforts to receive numerous grants from the U.S. National Institutes of Health and Department of Defense as well from other government and non-governmental organizations. She recently led Inovio's efforts to secure a $56 million funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to evaluate DNA vaccine candidates for Lassa fever and MERS through Phase 2 clinical testing. She will also be responsible for the oversight of a diverse preclinical R&D team encompassing discovery and development research, as well as operations, research DNA manufacturing and next-generation device development.
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.